# A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

> **NCT00545714** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 86 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00545714
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-21
- **Primary completion:** 2016-05-20
- **Final completion:** 2016-05-20
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545714, "A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00545714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*